Amneal Pharmaceuticals (AMRX) Stock: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$20.48
0.28 (1.39%)
▲
5d:
+6.39%
30d:
+5.95%
90d:
+14.29%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 03, 2026
11d
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AMRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AMRX shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.70
Based on 10.3% avg growth
INTRINSIC VALUE TODAY
$16.58
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $20.48, which is considered extended relative to its 30-day fair value range of $18.57 to $20.42. From a valuation perspective, the stock is trading at a premium (Forward PE: 17.2) compared to its historical average (13.8). At these levels, the market is pricing in 7.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $20.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.71 (+10.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AMRX is in a strong uptrend. The price is approaching resistance at $20.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $22.71 (+10.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$18.57 -
$20.42
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
Protect Your Profits
Holding AMRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($22.71)
- NEUTRAL: PE elevated vs history but 7.7% growth expectation is conservative given 157% recent growth
- WARNING: Composite score 51/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$18.57 -
$20.42
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$18.79
Resistance Level
$20.58
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.17
Wall Street Target
$22.71
(+10.9%)
Revenue Growth (YoY)
9.9%
Earnings Growth (YoY)
157.1%
Profit Margin
5.1%
Valuation Premium vs History
+7.7% premium
PE vs Historical
17.2 vs 13.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.7%
(market-implied from PE analysis)
1-Year Target
$22.06
(+8%)
2-Year Target
$23.76
(+16%)
3-Year Target
$25.58
(+25%)
3-Yr Target (if PE normalizes)
(PE: 17→14)
PE COMPRESSION
$20.56
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 16.5%)
$37.41
(+83%)
Base:
(SPY PE: 17.2, Growth: 16.5%)
$32.34
(+58%)
Bear:
(PE: 13.8, Growth: 16.5%)
$25.99
(+27%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 40.49 | Current EPS (TTM): $0.49
Bull Case
$43.65
(+116%)
Analyst growth 100.0%, PE expands to 44.5
Base Case
$39.68
(+96%)
Market implied 100.0%, PE stable at 40.5
Bear Case
$13.49
(-33%)
Severe decline -20.0%, PE contracts to 34.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 5:37 PM ET
Data refreshes hourly during market hours. Next update: 6:37 PM
Data refreshes hourly during market hours. Next update: 6:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
